Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rescue after intermediate and high-dose methotrexate: background, rationale, and current practice.

J D Borsi1, E Sagen, I Romslo

  • 1Department of Pediatrics, University of Trondheim, Norway.

Pediatric Hematology and Oncology
|January 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Health-associated reference values for arginine, asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) measured with high-performance liquid chromatography.

Scandinavian journal of clinical and laboratory investigation·2007
Same author

Results of a multilateral approach to donation-transplantation process in Hungary in the past 2 years.

Transplantation proceedings·2005
Same author

Screening for hemochromatosis: high prevalence and low morbidity in an unselected population of 65,238 persons.

Scandinavian journal of gastroenterology·2001
Same author

High-dose methotrexate in childhood all.

Pediatric hematology and oncology·2000
Same author

Iron deficiency anemia in a patient with excessive urinary iron loss.

European journal of haematology·2000
Same author

Variability in methotrexate serum and cerebrospinal fluid pharmacokinetics in children with acute lymphocytic leukemia: relation to assay methodology and physiological variables.

Leukemia research·2000

Folinic acid rescue is widely used with high-dose methotrexate, but optimal dosing and timing are unclear. Early administration may reduce methotrexate

Area of Science:

  • Pharmacology and Therapeutics
  • Oncology
  • Clinical Pharmacy

Background:

  • High-dose methotrexate (HDMTX) therapy requires pharmacologic rescue to mitigate toxicity.
  • Folinic acid (FA) is the standard rescue agent, but its optimal use remains debated.
  • Thymidine rescue has limited indications, primarily for methotrexate clearance delays.

Purpose of the Study:

  • To review pharmacologic rescue methods for intermediate and high-dose methotrexate.
  • To critically evaluate the mechanism, pharmacokinetics, and clinical application of nucleoside and folinic acid rescue.
  • To provide evidence-based recommendations for optimizing folinic acid rescue strategies.

Main Methods:

  • Comprehensive literature review of pharmacologic rescue agents, focusing on nucleosides and folinic acid.

Related Experiment Videos

  • Analysis of existing data on mechanism of action, pharmacokinetics, and clinical efficacy.
  • Inclusion of authors' findings and clinical observations.

    • Main Results:

    • Thymidine's clinical value is limited to specific scenarios of delayed methotrexate elimination.
    • Current folinic acid rescue protocols often use empirical dosing and early administration, potentially compromising efficacy.
    • Findings suggest lower FA doses and delayed administration may be sufficient for toxicity prevention and improved therapeutic outcomes.

    Conclusions:

    • The optimal mechanism, dose, and schedule for folinic acid rescue require further clarification.
    • Early FA administration can reduce methotrexate's antitumor effect; delayed administration is preferred.
    • Optimizing FA dosing, considering stereoisomers, and implementing therapeutic drug monitoring can enhance clinical utility.